Results 81 to 90 of about 1,367 (120)

Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl. [PDF]

Transl Vis Sci Technol, 2023
Ku CA, Igelman AD, Huang SJ, Vasconcelos H, da Palma MM, Bailey ST, Lauer AK, Weleber RG, Yang P, Pennesi ME.   +9 more
europepmc   +1 more source

New Gene Therapy Treatment for Retinitis Pigmentosa

, 2020
Objective: This study was conducted to educate health care professionals on Luxturna (Voretigene neparvovec), a novel FDA approved gene therapy for retinitis pigmentosa, and on identifying and testing procedure for potential candidates for the gene ...
Berezu, Tiana
core   +1 more source

Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. [PDF]

Cold Spring Harb Perspect Med, 2023
Bennett J, Maguire AM.
europepmc   +1 more source

Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. [PDF]

Graefes Arch Clin Exp Ophthalmol, 2022
Deng C, Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera TK, Khan N, Besirli CG.   +7 more
europepmc   +1 more source

Voretigene neparvovec for inherited retinal dystrophy. [PDF]

Aust Prescr, 2022
europepmc   +1 more source

Retinal Pigment Epithelium Atrophy After Subretinal Voretigene Neparvovec-rzyl for RPE65-Related Disease: A 6-Month Follow-Up. [PDF]

Retina, 2022
Giansanti F, Mucciolo DP, Sodi A, Giorgio D, Virgili G, Murro V.   +5 more
europepmc   +1 more source

Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Klinika Oczna
Martyna Mieszczak, Marika Pitnoczko, Kinga Obst, Zuzanna Niedziela-Schwartz, Piotr Rakowicz, Maciej Krawczyński, Marcin Stopa   +6 more
doaj   +1 more source

Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec. [PDF]

Ophthalmol Sci
Fischer MD, Audo I, Gaucher D, Holz FG, Kessel L, Russell S, Stingl K, Rousso DL, Maier R, Clemens A, Nagiel A, Leroy BP.   +11 more
europepmc   +1 more source

Clinical and pharmacovigilance safety evaluation of LUXTURNA^® (voretigene neparvovec-rzyl). [PDF]

Cutan Ocul Toxicol
Simoens D, Shravah V, Jones WK, Kaja S.
europepmc   +1 more source

Foveal detachment in voretigene neparvovec administration: essential step or avoidable risk? [PDF]

Eye (Lond)
Kiraly P, Ivanova T, Jalil A.
europepmc   +1 more source